Radiation showdown: which schedule beats childhood brain cancer?
NCT ID NCT01351870
First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 41 times
Summary
This study tested two different ways of giving radiation to children and teens with standard-risk medulloblastoma, a type of brain tumor. One group received standard daily radiation, while the other got smaller doses twice a day (hyperfractionated). The goal was to see which schedule better prevents the cancer from coming back. The trial enrolled 52 participants aged 4 to 21 and has already been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Curie
Paris, 75005, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (hyperfractionated vs. conventional)
What this could lead to
If successful, this could show that a different radiation schedule improves tumor control and survival for children with medulloblastoma.
What could go wrong
This is a completed phase 3 trial with only 52 participants, so results may not apply to all patients. Radiation can cause long-term side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.